The legal action centers on allegations that Embecta management repeatedly characterized its pen needle portfolio as resilient and stable, despite internal awareness of significant competitive share loss and retail market softening. These assurances were dismantled on May 5, 2026, when the company reported a sharp revenue decline and admitted to market headwinds that directly contradicted previous financial guidance.
Embecta Faces Securities Lawsuit Over Insulin Pen Needle Revenue Claims
Investors who suffered significant losses in Embecta Corp. have until August 17, 2026, to seek lead plaintiff status in a pending class action lawsuit. Hagens Berman is investigating claims that the medical device manufacturer misled shareholders about the stability of its core insulin pen needle business throughout late 2025 and early 2026.
Following the disclosure, Embecta slashed its full-year 2026 adjusted earnings per share forecast by approximately 43% and reduced its quarterly dividend by 93%, from $0.15 to $0.01 per share. The market reaction was swift, with the company's stock price dropping 57.8% in a single trading session. Reed Kathrein, the Hagens Berman partner overseeing the investigation, stated that the firm is scrutinizing whether these prior positive statements were intentionally misleading. Shareholders who purchased stock between November 25, 2025, and May 4, 2026, are being urged to contact the firm to review their potential recovery options.
Comments (0)
No comments yet. Be the first!